| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1; MAP2K2; MEK2; MKK2; PRKMK2; Dual specificity mitogen-activated protein k |
| Entrez GeneID | 5604/5605 |
| WB Predicted band size | Calculated MW: 43,44 kDa; Observed MW: 43,44 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Recombinant protein of human MEK1/2 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于MEK1/2抗体的3篇代表性文献摘要(模拟虚构内容，仅供参考格式)：
1. **文献名称**：*"Development and validation of a phospho-specific MEK1/2 antibody for monitoring ERK pathway activity in cancer"*
**作者**：Roberts PJ et al.
**摘要**：本研究开发了一种特异性识别磷酸化MEK1/2(Ser217/221)的单克隆抗体，验证了其在Western blot和免疫组化中的应用，证明其可敏感检测肿瘤样本中MAPK/ERK通路的激活状态。
2. **文献名称**：*"MEK1/2 antibody-based profiling reveals differential expression in BRAF-mutant melanomas"*
**作者**：Sullivan RJ et al.
**摘要**：通过高特异性MEK1/2抗体分析黑色素瘤组织，发现BRAF突变肿瘤中MEK1/2蛋白水平显著升高，提示其作为治疗反应预测标志物的潜力。
3. **文献名称**：*"A comparative study of commercial MEK1/2 antibodies for specificity and application in flow cytometry"*
**作者**：Chen H et al.
**摘要**：系统评估了市售MEK1/2抗体的交叉反应性和适用性，推荐克隆号XYZ-123用于流式细胞术检测T细胞活化中的MEK1/2表达。
(注：以上文献为示例，实际引用需查询真实数据库如PubMed。)
MEK1/2 (Mitogen-Activated Protein Kinase Kinase 1/2) antibodies are essential tools for studying the MAPK/ERK signaling pathway, a critical regulator of cell proliferation, differentiation, and survival. MEK1 and MEK2 are dual-specificity kinases that phosphorylate and activate ERK1/2. acting as central nodes in transmitting signals from growth factors, cytokines, and stress stimuli. Dysregulation of MEK1/2 is implicated in cancers, inflammatory diseases, and developmental disorders, making them therapeutic targets.
MEK1/2 antibodies are designed to detect either total MEK1/2 proteins or their activated (phosphorylated) forms, typically at conserved serine residues (e.g., Ser217/221 for MEK1). These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess MEK1/2 expression, activation status, and subcellular localization. Specificity varies; some antibodies distinguish MEK1 from MEK2. while others recognize both isoforms due to their high sequence homology (~80% identity).
In drug development, MEK1/2 antibodies help validate the efficacy of MEK inhibitors (e.g., trametinib, selumetinib) used in treating cancers like melanoma and NSCLC. They also serve as biomarkers in preclinical and clinical studies to monitor pathway inhibition or feedback mechanisms. Researchers must carefully select antibodies validated for their intended applications, as cross-reactivity or batch variability can affect data interpretation. Overall, MEK1/2 antibodies remain indispensable for unraveling pathway dynamics and advancing targeted therapies.
×
